Ascentage Pharma chairman buys 38,630 shares
The trustee’s scheme-related on-market holdings total 2,715,000 shares after the purchase, while Dr. Yang’s disclosed interest is 16.69% following his acquisitions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Ascentage Pharma Group International (AAPG) reported that the trustee for its 2022 RSU Scheme purchased 50,000 existing shares on-market on September 28, 2026, for HK$1,428,000, excluding related expenses, taxes and other charges. The average consideration was approximately HK$28.56 per share. The shares are held to satisfy RSUs upon vesting, and the trustee does not exercise their voting rights. Immediately after the purchase, the trustee had purchased 2,715,000 existing shares on-market for the scheme.
The company also reported that Chairman and Executive Director Dr. Dajun Yang acquired 38,630 shares on-market on September 23, September 24 and September 25, 2026, for total consideration of approximately HK$1,157,137 and an average price of approximately HK$29.95 per share. Afterward, he was deemed interested in 62,570,254 shares, representing approximately 16.69% of issued share capital. The company said Dr. Yang advised that the acquisitions indicate his confidence in its prospects.
Key Figures
Key Terms
2022 RSU Scheme technical
on-market financial
deemed to be interested regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of September 2026
Commission File Number: 001-42484
ASCENTAGE PHARMA GROUP INTERNATIONAL
(Translation of Registrant’s name into English)
68 Xinqing Road
Suzhou Industrial Park
Suzhou, Jiangsu
China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On September 28, 2026, Ascentage Pharma Group International (“Ascentage Pharma” or the “Company”) posted two announcements on the Hong Kong Stock Exchange entitled, “PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME” and “ACQUISITION OF SHARES BY THE CHAIRMAN AND EXECUTIVE DIRECTOR A copy of the announcements are furnished as Exhibits 99.1 and 99.2 to this Report.
INDEX TO EXHIBITS
| Exhibit Number |
Exhibit Title | |
| 99.1 | RSU Purchase Announcement dated September 28, 2026 | |
| 99.2 | Chairman Purchase Announcement dated September 28, 2026 |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ASCENTAGE PHARMA GROUP INTERNATIONAL | ||
| Date: September 28, 2026 | /s/ Dajun Yang | |
| Name: | Dajun Yang | |
| Title: | Chief Executive Officer | |
2
Exhibit 99.1
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
ASCENTAGE PHARMA GROUP INTERNATIONAL
亞 盛 醫 藥 集 團
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6855)
VOLUNTARY ANNOUNCEMENT
PURCHASE OF SHARES BY THE TRUSTEE
FOR THE PURPOSE OF THE 2022 RSU SCHEME
This announcement is made by Ascentage Pharma Group International (the “Company”) on a voluntary basis. Reference is made to the announcements of the Company dated June 23, 2022, July 14, 2022, October 21, 2022, October 25, 2022, October 26, 2022, October 27, 2022, October 28, 2022, October 31, 2022, May 8, 2023, November 13, 2023, November 14, 2023, November 16, 2023, February 2, 2024, September 2, 2024, October 24, 2024, March 31, 2025, April 8, 2025, April 30, 2025, June 27, 2025, November 27, 2025, December 30, 2025, April 20, 2026, April 30, 2026, May 27, 2026, May 28, 2026, June 10, 2026, June 11, 2026, June 29, 2026, July 13, 2026 and September 17, 2026 (the “Announcements”) in relation to, among other things, (i) the adoption of and amendments to the 2022 RSU Scheme; (ii) the initial grant and the further grants of the 2022 Awards thereunder; and (iii) the purchase of existing Shares by the Trustee on-market for the purpose of the 2022 RSU Scheme. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcements.
On September 28, 2026, the Trustee purchased a total of 50,000 existing Shares (the “Purchased Shares”) on-market for the purpose of the 2022 RSU Scheme to satisfy the RSUs upon vesting. Details of the Purchased Shares and the latest information about the Shares held by the Trustee under the Scheme are as follows:
| Purchase date | : | September 28, 2026 |
| Total number of the Purchased Shares | : | 50,000 Shares |
| Percentage of the Purchased Shares to the total number of issued Shares as at the date of this announcement | : | Approximately 0.01% |
| Total consideration paid for the Purchased Shares (excluding all related expenses, transaction levy, brokerage, tax, duties and levies) | : | HK$1,428,000 |
| Average consideration per Purchased Share (excluding all related expenses, transaction levy, brokerage, tax, duties and levies) | : | Approximately HK$28.56 |
| Total number of existing Shares purchased by the Trustee on-market for the purpose of the 2022 RSU Scheme immediately after the aforesaid purchases | : | 2,715,000 Shares |
The Purchased Shares are currently held by the Trustee in accordance with the 2022 RSU Scheme Rules and the terms of the trust deed entered into between the Company and the Trustee. The Trustee shall not exercise the voting rights attached to the Shares held on trust by it. As at the date of this announcement, no further grant of Awards has been made pursuant to the 2022 RSU Scheme apart from the initial grant of the 2022 Awards on June 23, 2022 and the further grants of the 2022 Awards on May 4, 2023, September 2, 2024, June 27, 2025, November 26, 2025, April 20, 2026 and June 29, 2026 as disclosed in the Announcements.
| By Order of the Board | |
| Ascentage Pharma Group International Dr. Yang Dajun | |
| Chairman and Executive Director |
Suzhou, People’s Republic of China, September 28, 2026
As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon DazhongNote 1 as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky Note 2, Ms. Marina S. Bozilenko, Dr. Debra Yu and Dr. Marc E. Lippman, MD as independent non-executive Directors.
Notes:
| 1. | Dr. Lu Simon Dazhong satisfies the independence requirements of the U.S. Securities and Exchange Commission and Nasdaq corporate governance requirements. |
| 2. | Dr. David Sidransky is the Lead Independent Non-Executive Director of the Company. |
Exhibit 99.2
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
ASCENTAGE PHARMA GROUP INTERNATIONAL
亞 盛 醫 藥 集 團
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6855)
VOLUNTARY ANNOUNCEMENT
ACQUISITION OF SHARES BY
THE CHAIRMAN AND EXECUTIVE DIRECTOR
This announcement is a voluntary announcement made by Ascentage Pharma Group International (the “Company”).
The Company was notified by Dr. Yang Dajun (“Dr. Yang”), an executive director and the chairman of the board of directors of the Company that, on September 23, 2026, September 24, 2026, and September 25, 2026, he has acquired an aggregate of 38,630 ordinary shares of the Company (the “Shares”) on-market at a total consideration of approximately HK$1,157,137 with an average price of approximately HK$29.95 per Share, representing approximately 0.01% of the total issued share capital of the Company as at the date of this announcement (collectively, the “Acquisitions”).
As at the date of this announcement, Dr. Yang is deemed to be interested in an aggregate of 62,531,624 Shares pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) through interest as beneficial owner, interests held jointly with other persons, interest of spouse and being the settlor of a discretionary trust (please refer to the section headed “Directors’ and Chief Executives’ Interests and Short Positions in Shares and Underlying Shares and Debentures of the Company or any of its Associated Corporations” in the interim report of the Company for the six months ended June 30, 2026 for further details). As such, following the completion of the Acquisitions, Dr. Yang will be deemed to be interested in an aggregate of 62,570,254 Shares, representing approximately 16.69% of the total issued share capital of the Company as at the date of this announcement.
As advised by Dr. Yang, the Acquisitions indicate his confidence in the prospects of the Company.
The Acquisitions were conducted in compliance with applicable laws, rules and regulations, including the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Company’s own code of conduct regarding securities transactions, namely the policy on management of securities transactions by directors.
Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.
| By Order of the Board | |
| Ascentage Pharma Group International Dr. Yang Dajun | |
| Chairman and Executive Director |
Suzhou, People’s Republic of China, September 28, 2026
As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon DazhongNote 1 as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky Note 2, Ms. Marina S. Bozilenko, Dr. Debra Yu and Dr. Marc E. Lippman, MD as independent non-executive Directors.
Notes:
| 1. | Dr. Lu Simon Dazhong satisfies the independence requirements of the U.S. Securities and Exchange Commission and Nasdaq corporate governance requirements. |
| 2. | Dr. David Sidransky is the Lead Independent Non-Executive Director of the Company. |